[ CAS No. 63-64-9 ]

Name: 63-64-9|N-Methyl-3,4-dimethoxybenzylamine|95%
Brand: Ambeed
SKU: A531810
Price: 14.0 USD
Availability: InStock
Rating: 94 (30 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 63-64-9

Structure of 63-64-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 100K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 63-64-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 63-64-9 ]

SDS Specification

Alternatived Products of [ 63-64-9 ]

Product Details of [ 63-64-9 ]

CAS No. :	63-64-9	MDL No. :	MFCD00837593
Formula :	C₁₀H₁₅NO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	XQODFBIAQVJQHF-UHFFFAOYSA-N
M.W :	181.23	Pubchem ID :	592161
Synonyms :

Calculated chemistry of [ 63-64-9 ]

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.4
Num. rotatable bonds :	4
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	52.0
TPSA :	30.49 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.79 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.47
Log Po/w (XLOGP3) :	0.86
Log Po/w (WLOGP) :	1.27
Log Po/w (MLOGP) :	1.22
Log Po/w (SILICOS-IT) :	1.86
Consensus Log Po/w :	1.54

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.58
Solubility :	4.73 mg/ml ; 0.0261 mol/l
Class :	Very soluble
Log S (Ali) :	-1.08
Solubility :	14.9 mg/ml ; 0.0824 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-3.5
Solubility :	0.0578 mg/ml ; 0.000319 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.33

Safety of [ 63-64-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 63-64-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 63-64-9 ]

[ 63-64-9 ] Synthesis Path-Downstream 1~68

1
[ 27602-80-8 ]
[ 63-64-9 ]
3-(methyl-veratryl-amino)-1-(3.4-dimethoxy-phenyl)-propanol-⁽²⁾ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1946,vol. 68,p. 201

2
[ 859741-89-2 ]
[ 63-64-9 ]
N,N,N',N'-tetramethyl-N,N'-diveratryl-N,N'-(3,14-dioxa-hexadecanediyl)-di-ammonium; diperchlorate [ No CAS ]

Reference： [1]Patent: DE957036,1953,

3
[ 63-64-9 ]
[ 125789-62-0 ]

Reference： [1]Bulletin de la Societe Chimique de France,1911,vol. <4> 9,p. 932

4
[ 5437-82-1 ]
[ 63-64-9 ]
N',N'-Diethyl-β-(N-methyl-3,4-dimethoxy-benzylamino)-propionamid [ No CAS ]

Reference： [1]Journal of medicinal and pharmaceutical chemistry,1960,vol. 2,p. 617 - 631

5
[ 60028-86-6 ]
[ 63-64-9 ]

Reference： [1]Journal of medicinal and pharmaceutical chemistry,1960,vol. 2,p. 617 - 631

6
[ 63-64-9 ]
[ 85175-59-3 ]
3-{3-[(3,4-Dimethoxy-benzyl)-methyl-amino]-propyl}-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1990,vol. 33,p. 1496 - 1504

7
[ 63-64-9 ]
[ 114432-17-6 ]
[ 114432-94-9 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 981 - 988

8
[ 63-64-9 ]
[ 114432-46-1 ]
[ 138697-53-7 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 981 - 988

9
[ 63-64-9 ]
[ 532-27-4 ]
[ 128942-54-1 ]

Reference： [1]Synthesis,1990,p. 253 - 255

10
[ 63-64-9 ]
[ 70-11-1 ]
[ 128942-54-1 ]

Reference： [1]Synthesis,1990,p. 253 - 255

11
[ 63-64-9 ]
[ 2032-35-1 ]
[ 78373-65-6 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1992,p. 1613 - 1616

12
6-benzyl-3-tert-butoxycarbonyl-4,5,6,7-tetrahydro-2-(4-nitrophenoxycarbonylamino)thieno[2,3-c]pyridin-6-ium hydrochloride [ No CAS ]
[ 63-64-9 ]
[ 872531-10-7 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 8270 - 8288

13
[ 63-64-9 ]
[ 2169-98-4 ]

Reference： [1]Synthetic Communications,2005,vol. 35,p. 2445 - 2451

14
[ 63-64-9 ]
2-[4,8-bis-[(3,4-dimethoxy-benzyl)-methyl-amino]-6-(2-hydroxy-ethylamino)-pyrimido[5,4-d]pyrimidin-2-ylamino]-ethanol [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 4905 - 4922

15
[ 63-64-9 ]
1-[4,8-bis-[(3,4-dimethoxy-benzyl)-methyl-amino]-6-(2-hydroxy-propylamino)-pyrimido[5,4-d]pyrimidin-2-ylamino]-propan-2-ol [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 4905 - 4922

16
[ 63-64-9 ]
3-[4,8-bis-[(3,4-dimethoxy-benzyl)-methyl-amino]-6-(3-hydroxy-propoxy)-pyrimido[5,4-d]pyrimidin-2-yloxy]-propan-1-ol [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 4905 - 4922

17
[ 63-64-9 ]
4-{3-[(3,4-Dimethoxy-benzyl)-methyl-amino]-propyl}-2-methyl-phenylamine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

18
[ 63-64-9 ]
[ 143665-57-0 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426
[2]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

19
[ 63-64-9 ]
[ 143667-02-1 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

20
[ 63-64-9 ]
[ 143666-74-4 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

21
[ 63-64-9 ]
[ 163981-87-1 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

22
[ 63-64-9 ]
[ 143665-53-6 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

23
[ 63-64-9 ]
[ 143665-56-9 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

24
[ 63-64-9 ]
N-[4-[4-[[(3,4-dimethoxyphenyl)methyl]methylamino]butyl]phenyl]-9,10-dihydro-9-oxo-4-acridinecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426
[2]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

25
[ 63-64-9 ]
N-[4-[5-[[(3,4-Dimethoxyphenyl)methyl]methylamino]pentyl]phenyl]-9,10-dihydro-9-oxo-4-acridinecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

26
[ 63-64-9 ]
N-[4-[[3-[[(3,4-dimethoxyphenyl)methyl]methylamino]propyl]thio]phenyl]-9,10-dihydro-9-oxo-4-acridinecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

27
[ 63-64-9 ]
N-[4-[4-[[(3,4-Dimethoxyphenyl)methyl]methylamino]-2-butenyl]phenyl]-9,10-dihydro-9-oxo-4-acridinecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

28
[ 63-64-9 ]
5-Amino-N-[4-[4-[[(3,4-dimethoxyphenyl)methyl]methylamino]butyl]phenyl]-9,10-dihydro-9-oxo-4-acridinecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426
[2]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

29
[ 63-64-9 ]
N-[4-[4-[[(3,4-Dimethoxyphenyl)methyl]methylamino]butyl]phenyl]-9,10-dihydro-7-methoxy-9-oxo-4-acridinecarboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426
[2]Journal of Medicinal Chemistry,1995,vol. 38,p. 2418 - 2426

30
[ 63-64-9 ]
[ 143426-22-6 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1992,p. 1613 - 1616

31
[ 63-64-9 ]
[ 143426-26-0 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1992,p. 1613 - 1616

32
[ 63-64-9 ]
[ 143426-17-9 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1992,p. 1613 - 1616

33
[ 63-64-9 ]
[ 74828-31-2 ]

Reference： [1]Journal of the American Chemical Society,1980,vol. 102,p. 6513 - 6519

34
[ 63-64-9 ]
[ 128942-60-9 ]

Reference： [1]Synthesis,1990,p. 253 - 255
[2]Synthesis,1990,p. 253 - 255

35
[ 63-64-9 ]
1,2-Dihydro-2-methyl-4-phenyl-6,7-dimethoxyisoquinoline [ No CAS ]

Reference： [1]Synthesis,1990,p. 253 - 255
[2]Synthesis,1990,p. 253 - 255

36
[ 63-64-9 ]
[ 55178-75-1 ]

Reference： [1]Synthesis,1990,p. 253 - 255
[2]Synthesis,1990,p. 253 - 255
[3]Synthesis,1990,p. 253 - 255
[4]Synthesis,1990,p. 253 - 255
[5]Synthesis,1990,p. 253 - 255
[6]Synthesis,1990,p. 253 - 255

37
ethereal citric acid [ No CAS ]
[ 63-64-9 ]
[ 145654-01-9 ]
4-Methoxy-3-propargyloxy-1-[[N-(methyl)-(3,4-dimethoxyphenethyl)amino]methyl]benzene Citrate Monohydrate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; sodium tris(acetoxy)borohydride; In diethyl ether; dichloromethane; 1,2-dichloro-ethane;	EXAMPLE 22 4-Methoxy-3-propargyloxy-1-[[N-(methyl)-(3,4 dimethoxyphenethyl)amino]methyl]benzene Citrate Monohydrate To a solution of 4-methoxy-3-propargyloxybenzaldehyde(5.07 g) in 1,2-dichloroethane(50 ml) was added <strong>[63-64-9]N-methylveratrylamine</strong> (4.9 ml) followed by sodium triacetoxyborohydride (8.48 g), with stirring. The reaction mixture was stirred at ambient temperature for 1 hr, 1,2-dichloroethane (50 ml) was added, and the reaction mixture stirred at ambient temperature for 0.5 hr. The reaction mixture was poured into ice/10% sodium hydroxide solution (250 ml) and extracted with chloroform. The organic extracts were combined, washed with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was dissolved in dichloromethane and high performance liquid chromatographed, eluding with 2% methanol:dichloromethane. The appropriate fractions were collected and concentrated to give 8.27 g (84%) of product, as the free base. The free base was dissolved in diethyl ether, and ethereal citric acid was added. The precipitate was collected to give product, mp 40-80 C. Analysis: Calculated for C28H37NO12: 58.02%; C, 6.43%; H, 2.42%; N, Found: 58.19%; C, 6.21%; H, 2.27%; N.

Reference： [1]Patent: US6479495,2002,B1

38
[ 120-14-9 ]
[ 63-64-9 ]

Yield	Reaction Conditions	Operation in experiment
	With methylamine;palladium-carbon; In ethanol; water; toluene;	REFERENCE EXAMPLE 1 Preparation of N-(3,4-dimethoxybenzyl)methylamine 41.5 g (0.25 mol) of veratraldehyde was suspended in 100 ml of water, and 29 ml of a 40% methylamine aqueous solution was dropwise added over a period of 15 minutes under cooling with ice. The mixture was stirred overnight at room temperature. 500 ml of toluene was added to the reaction solution. The organic layer was separated, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain 49.8 g of oily residue of N-(3,4-dimethoxybenzylidene)methylamine. This oily residue was dissolved in 300 ml of ethanol, and 10 g of 10% palladium carbon was added. Under a hydrogen gas stream, catalytic reduction was conducted for 7 hours. The catalyst was removed from the reaction solution, and the solvent was distilled off under reduced pressure to obtain 45 g (yield: 100%) of the above identified compound as oily residue. NMRdelta(CDCl3): 1.67(1H, s), 2.45(3H, s), 3.68(2H, s), 3.89(6H, s), 6.80-6.95(3H, m)

Reference： [1]Patent: US4987235,1991,A

39
3-chloro-N-3-(trifluoromethyl)phenyl-propanesulfonamide [ No CAS ]
[ 63-64-9 ]
3-[[(3,4-Dimethoxyphenyl)methyl]methylamino]-N-[3-(trifluoromethyl)phenyl]propanesulfonamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In 5,5-dimethyl-1,3-cyclohexadiene;	EXAMPLE 12 3-[[(3,4-Dimethoxyphenyl)methyl]methylamino]-N-[3-(trifluoromethyl)phenyl]propanesulfonamide The title compound was prepared by reaction of 3-chloro-N-3-(trifluoromethyl)phenyl-propanesulfonamide with N-methyl-3,4-dimethoxybenzylamine in xylene as in previous examples. Analysis for: C20 H25 N2 O4 SF3: Calculated: C, 53.80; H, 5.64; N, 6.27. Found: C, 53.34; H, 5.62; N, 6.04.
	In 5,5-dimethyl-1,3-cyclohexadiene;	EXAMPLE 12 3-[[(3,4-Dimethoxyphenyl)methyl]methylamino]-N-[3-(trifluoromethyl)phenyl]propanesulfonamide The title compound was prepared by reaction of 3-chloro-N-3-(trifluoromethyl)phenyl-propanesulfonamide with N-methyl-3,4-dimethoxybenzylamine in xylene as in previous examples. Analysis for C20 H25 N2 O4 SF3: Calculated: C, 53.80; H, 5.64; N, 6.27; Found: C, 53.34; H, 5.62; N, 6.04.

Reference： [1]Patent: US4587360,1986,A
[2]Patent: US4539426,1985,A

40
[ 63-64-9 ]
[ 155868-60-3 ]
1-Methyl-3-{6-[N-methyl-N-(3,4-dimethoxybenzyl)amino]hexanoyl}indole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 78 1-Methyl-3-{6-[N-methyl-N-(3,4-dimethoxybenzyl)amino]hexanoyl}indole (Compound No. 1-293) A procedure similar to that described in Example 53 was repeated, but using 1-methyl-3-(6-bromohexanoyl)indole and N -methyl- N -(3,4-dimethoxybenzyl)amine as starting materials, in relative proportions similar to those used in that Example, to obtain the title compound as an oil, with an Rf value of 0.30, using ethyl acetate as developing solvent.

Reference： [1]Patent: EP562832,1993,A1

41
trichloromethyl chloroformate ("diphosgene") [ No CAS ]
[ 63-64-9 ]
[ 120-14-9 ]
[ 426813-77-6 ]

Yield	Reaction Conditions	Operation in experiment
	In pyridine;	V. Synthesis of 3,4-dimethoxybenzyl(methyl)carbamoyl Chloride 1.00 g (5.52 mmol) of 3,4-dimethoxybenzyl-N-methylamine (obtainable by reductive amination from 3,4-dimethoxybenzaldehyde) are dissolved in 20 ml of anhydrous pyridine. 0.60 g (0.37 mmol, 3.04 mmol) of trichloromethyl chloroformate ("diphosgene") is added, and the mixture is left to stir at room temperature overnight. The solution is employed without workup directly in the next stage.

Reference： [1]Patent: US2004/82596,2004,A1

42
[ 17972-14-4 ]
[ 63-64-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 2499 - 2512
[2]Helvetica Chimica Acta,2009,vol. 92,p. 2754 - 2761

43
[ 63-64-9 ]
[ 1025423-95-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 2499 - 2512

44
[ 959757-97-2 ]
[ 63-64-9 ]
[ 1147090-59-2 ]

Reference： [1]Tetrahedron,2009,vol. 65,p. 2655 - 2659

45
[ 63-64-9 ]
[ 359868-65-8 ]
[ 1147090-58-1 ]

Reference： [1]Tetrahedron,2009,vol. 65,p. 2655 - 2659

46
[ 63-64-9 ]
[ 122-78-1 ]
[ 536-74-3 ]
[ 1161830-98-3 ]

Reference： [1]Angewandte Chemie - International Edition,2009,vol. 48,p. 3116 - 3120

47
[ 50-00-0 ]
[ 64-17-5 ]
[ 63-64-9 ]
[ 1208333-36-1 ]

Reference： [1]Helvetica Chimica Acta,2009,vol. 92,p. 2754 - 2761

48
[ 5326-23-8 ]
[ 63-64-9 ]
[ 1227299-76-4 ]

Yield	Reaction Conditions	Operation in experiment
77%	at 150℃;	A mixture of 5.0 g (31.7 mmol) of 6-chloronicotinic acid and 15.1 ml (79.4 mmol) of 3,4-dimethoxy-N-methylbenzylamine was heated at 150 C. overnight, while stirring. After cooling to RT, 300 ml of ethyl acetate and 600 ml of water were added. The solid formed was filtered off in the course of the phase separation and dried in vacuo. 7.38 g (77% of th.) of the title compound were obtained.1H-NMR (400 MHz, CDCl3, delta/ppm): 8.91 (d, 1H), 8.07-8.02 (dd, 1H), 6.81 (d, 1H), 6.78-6.73 (m, 2H), 6.52 (d, 1H), 4.82 (d, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 3.12 (s, 3H).LC/MS (method I, ESIpos): Rt=0.74 min, m/z=303 [M+H]+.
77%	at 150℃;	Step 1: 6-[(3,4-Dimethoxybenzyl)(methyl)amino]nicotinic acid With stirring, a mixture of 5.0 g (31.7 mmol) of 6-chloronicotinic acid and 15.1 ml (79.4 mmol) of 3,4-dimethoxy-N-methylbenzylamine was heated at 150 C. overnight. After cooling to RT, 300 ml of ethyl acetate and 600 ml of water were added. The solid formed was removed during phase separation and dried under reduced pressure. This gave 7.38 g (77% of theory) of the title compound. 1H NMR (400 MHz, CDCl3, delta/ppm): 8.91 (d, 1H), 8.07-8.02 (dd, 1H), 6.81 (d, 1H), 6.78-6.73 (m, 2H), 6.52 (d, 1H), 4.82 (d, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 3.12 (s, 3H). LC/MS (Method 5, ESIpos): Rt=0.74 min, m/z=303 [M+H]+.

Reference： [1]Patent: US2011/301122,2011,A1 .Location in patent: Page/Page column 66
[2]Patent: US2013/150325,2013,A1 .Location in patent: Paragraph 0736; 0737; 0738; 0739

49
[ 5326-23-8 ]
[ 63-64-9 ]
[ 1227299-80-0 ]

Reference： [1]Patent: US2011/301122,2011,A1
[2]Patent: US2013/150325,2013,A1

50
[ 1225380-34-6 ]
[ 63-64-9 ]
[ 1227299-96-8 ]

Yield	Reaction Conditions	Operation in experiment
	at 150℃;Inert atmosphere;	A mixture of 1.0 g (3.97 mmol) of the compound from Example 45A and 3.8 ml (19.9 mmol) of 3,4-dimethoxy-N-methylbenzylamine was heated at 150 C. under argon overnight, while stirring. After cooling to RT, ethyl acetate and water were added, the phases were separated and the aqueous phase was extracted three times with ethyl acetate. These ethyl acetate extracts were discarded. The aqueous phase was then first adjusted to a pH of 3 with 1 M hydrochloric acid, extracted four times with ethyl acetate, then adjusted to a pH of 7 with sodium bicarbonate solution and extracted again three times with ethyl acetate. The combined ethyl acetate phases were dried over magnesium sulphate, filtered and concentrated. After the residue had been dried in vacuo, 839 mg (49% of th., purity of 92%) of the title compound were obtained.1H-NMR (400 MHz, CDCl3, delta/ppm): 8.10 (s, 1H), 7.32 (d, 1H), 6.81-6.70 (m, 3H), 6.61 (s, 1H), 6.46 (d, 1H), 5.21 (s, 2H), 4.70 (s, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 3.04 (s, 3H), 2.25 (s, 3H).LC/MS (method I, ESIpos): Rt=0.66 min, m/z=397 [M+H]+.

Reference： [1]Patent: US2011/301122,2011,A1 .Location in patent: Page/Page column 67

51
[ 63-64-9 ]
[ 536-74-3 ]
[ 563-96-2 ]
N-(3,4-dimethoxybenzyl)-N-methyl-1,5-diphenylpent-1-en-4-yn-3-amine [ No CAS ]

Reference： [1]Organic Letters,2012,vol. 14,p. 1942 - 1945

52
[ 63-64-9 ]
[ 590-86-3 ]
[ 471-25-0 ]
[ 1376386-82-1 ]

Reference： [1]Journal of Organic Chemistry,2012,vol. 77,p. 5149 - 5154

53
C₁₇H₁₅ClN₂O₂ [ No CAS ]
[ 63-64-9 ]
[ 1001192-43-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 4396 - 4403

54
C₁₅H₁₀Cl₂N₂O₂ [ No CAS ]
[ 63-64-9 ]
[ 1001192-21-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 4396 - 4403

55
[ 6773-29-1 ]
[ 63-64-9 ]
[ 1393678-70-0 ]

Reference： [1]Journal of the American Chemical Society,2012,vol. 134,p. 13565 - 13568

56
[ 63-64-9 ]
(E)-1-(2-((3,4-dimethoxybenzyl)(methyl)amino)phenyl)-3-(phenyl)prop-2-en-1-one [ No CAS ]